SCHEMBL4152135

SCHEMBL4152135

CC1CCC(C(=O)N(c2cc(-c3ccc(-c4cn5ccccc5n4)cc3)sc2C(=O)O)C(C)C)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
KDM4E B2RXH2 12/20 0.43
ALDH1A1 P00352 7/20 0.43
SMN1; SMN2 Q16637 7/20 0.43
HPGD P15428 6/20 0.43
FASN P49327 1/20 0.43
RAB9A P51151 6/20 0.39
NPC1 O15118 4/20 0.39
GFER P55789 3/20 0.39
HDAC6 Q9UBN7 1/20 0.39
LMNA P02545 3/20 0.39
POLB P06746 1/20 0.39
HSD17B10 Q99714 3/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
PKM P14618 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152130 1.00 PTGS1 (0.45) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4155723 0.91 KDM4E (0.43) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4155724 0.91 KDM4E (0.43) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4147202 0.91 PTGS1 (0.42) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4147205 0.91 PTGS1 (0.42) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4140546 0.88 KDM4E (0.35) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4140544 0.88 KDM4E (0.35) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL5404572 0.87 PTGS1 (0.45) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL5404565 0.87 PTGS1 (0.45) PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2
SCHEMBL4143244 0.86 TP53 (0.46) ALDH1A1SMN1; SMN2HPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US claimed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS PTGS1 2092/4885PTGS2 2027/4885KDM4E 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.